Skip to main content
Fig. 4 | Alzheimer's Research & Therapy

Fig. 4

From: Pharmacokinetics and pharmacodynamic effect of crenezumab on plasma and cerebrospinal fluid beta-amyloid in patients with mild-to-moderate Alzheimer’s disease

Fig. 4

Serum crenezumab and total plasma Aβ Ctrough concentrations. Total number of patients included = 130. Circles represent data from the phase II ABBY and BLAZE studies for all patients for 300 mg q2w SC and 15 mg/kg q4w IV, and from the phase Ib GN29632 study for 30–120 mg/kg q4w IV from weeks 5, 9, and 13. Solid lines and shaded areas represent the median and 5–95% prediction intervals, respectively, based on target-mediated drug disposition model predictions. Abbreviations: Aβ beta-amyloid, Ctrough pre-dose serum crenezumab, IV intravenous, q2w every 2 weeks, q4w every 4 weeks, SC subcutaneous

Back to article page